Active material: Ftoruracil
When ATH: L01BC02
CCF: Anticancer drug. Antimetaʙolit
When CSF: 22.02.03
Manufacturer: TEVA Pharmaceutical Industries Ltd. (Israel)
Solution for injection clear, colorless to slightly yellow, free of mechanical impurities.
| 1 ml | 1 fl. | |
| ftoruracil | 50 mg | 250 mg |
Excipients: Sodium hydroxide, water d / and.
5 мл – флаконы (1) – пачки картонные.
Solution for injection clear, colorless to slightly yellow, free of mechanical impurities.
| 1 ml | 1 fl. | |
| ftoruracil | 50 mg | 500 mg |
Excipients: Sodium hydroxide, water d / and.
10 мл – флаконы (1) – пачки картонные.
Group of antimetabolites antineoplastic. Is antimetabolitom uracil, competes with it for timidilatsintetazu, blocking DNA synthesis, raises education structurally imperfect RNA (by introducing in its synthesis), oppressing Division of tumor cells. A few hours later the concentration in tumor tissue above, than in healthy tissue.
Ftoruacil is a part of many schemes to cytostatic treatment, Therefore when choosing a route, regime and doses in each individual case data should guide literature.
Misleading in/in struino or drip, B / A (It is recommended that you use the appropriate infusion pump to ensure constant infusion rate), intracisternally.
B / drip, for any of the following schemes (введение прекращают при появлении побочных эффектов – стоматита, diarrhea, leukopenia or thrombocytopenia; resume after an increase in the number of leukocytes to 3-4 thousand / μl and platelets up to 80-100 thous. / ul): 1) 1 g/m2/day/drip constantly over 96-120 no; 2) 600 mg/sq ft/in 1 and 8 days of the course, in combination with other. PM.
When used in combination with calcium folinatom dose fluorouracil is usually reduced by 25-30%; 3) 500 mg/m2 or 12-13.5 mg/kg each day for 3-5 days, интервал между курсами – 4 Sun; 4) 600 mg/m2 or 15 mg / kg (The highest single dose 1 g) 1 Once a week for 6-10 Sun.
When used in combination with calcium folinatom dose fluorouracil is usually reduced by 25-30%. In obese patients or patients with elevated body mass due to edema, ascites, etc. causes of fluid retention, it is recommended to estimate body mass without taking them into account (“сухая” масса).
From the digestive system: decreased appetite, nausea, vomiting, heartburn, taste disturbance, esophagitis, inflamed and ulcerated mucous membrane syndrome, ulcerative stomatitis, diarrhea, bleeding from the gastrointestinal tract, abnormal liver function.
From the CCC: myocardial ischemia (angina, LV failure, breathlessness), which can be observed for a few hours later the introduction; usually develops in the second or later posledstviiduûŝih introductions; myocardial infarction, thrombophlebitis at the injection site.
From the central nervous system: acute cerebellar syndrome (ataxia, nistagmo), headache, disorientation, confusion, euphoria.
From the side of hematopoiesis: leukopenia (usually via 9-14 days later each course; the lowest level is a 9-14, реже – 20 days; restored after about 30 days), neutropenia, anemia, thrombocytopenia.
From the senses: optic neuritis, lacrimation, sleznыh ducts stenosis, blurred vision, photophobia, Cataract, korkovaya blindness (at higher doses). Allergic reactions: skin rash, dermatitis, hives, photosensitivity, bronchospasm, anaphylactic shock.
For the skin: dermatomelasma, dry and cracked skin, hand-foot syndrome eritrodizestezii (tingling sensation in hands and feet with the advent of posledstviiduûŝim pain, hyperemia and swelling), alopecia, teleangiэktaziya, nail changes (incl. the destruction of).
Other: azoospermia, amenorrhea, hyperuricemia, pneumopathy (cough, breathlessness), epistaxis (nose bleed), weakness (usually occurs immediately afterwards introduction and kept for 12-36 no), development of secondary infections.
C care. Renal and / or hepatic insufficiency, acute infectious viral disease, fungal or bacterial origin (incl. tuberculosis, enable vetryanaya, shingles), bone marrow infiltration of tumor cells, previously carried out intense radiation or chemotherapy, kaxeksija.
The reception of the product contraindicated.
With the emergence of stomatitis or diarrhea treatment product must stop until these symptoms.
With the development of the syndrome, Palmar-Plantar èritrodizestezii appointment inside pyridoxine dose 100-150 mg / day.
During treatment should monitor the total number of leukocytes and platelets, determine the hematocrit and Hb, activity of AST, GOLD, LDH, bilirubin, inspect the oral cavity of the ill to detect ulcers (before each product introduction).
Patients with advanced lakopenia should be carefully observed for signs of infection.
Data on overdose are not represented.
The efficacy and/or toxicity increase etc. antineoplastic HP (Interferon al′fa2a, cyclophosphamide, vynkrystyn, methotrexate, cisplatin, adriamycin), calcium folinate.
Лучевая терапия – аддитивное угнетение костного мозга. When duty coupled with mitomycine c observed the emergence of haemolytic uraemic syndrome.
Together with the admission sorivudinom noted the expressed lakopenia, in some cases leading to death.
Fluorouracil not be used later, in conjunction with therapy aminofenazonom, fenilbutazonom and sul′fonamidom. Hlordiazeopoksid, disulьfiram, griseofulvin and isoniazid may increase the activity of fluorouracil.
In connection with the Suppression of natural protective mechanisms in the treatment of fluorouracil possible vaccine virus replication process intensification or reduction of the production of antibodies in response to the introduction of the vaccine in the vaccination of live or inactivated vaccines, Therefore, the interval between the end of the product application and vaccinating live or inactivated vaccines is from 3 to 12 Months.
At a temperature of 15-30° c.
Shelf life - 2 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More